Novel therapeutic targets in multiple myeloma

European Journal of Haematology

Volumn 64, Issue 6, 2000, Pages 359-367

  Davies, Faith E ^a   Anderson, Kenneth C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adhesion molecules; Angiogenesis; Bone marrow microenvironment; IL 6; Multiple myeloma; Novel treatment; Serotherapy

Indexed keywords

CELL SURFACE PROTEIN; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; THALIDOMIDE; VINCRISTINE;

ANGIOGENESIS; CANCER SURVIVAL; CELL GROWTH; CELL SURVIVAL; DRUG ACTIVITY; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REMISSION; REVIEW;

BONE MARROW; CELL ADHESION MOLECULES; CELL DIVISION; CELL SURVIVAL; CYTOKINES; HUMANS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033937720     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.9R233.x     Document Type: Review

References (74)

1. 1. ATTAL M, HAROUSSEAU JL, STOPPA AM, SOTTO JJ, FUZIBET JG, ROSSI JF, CASASSUS P, MAISONNEUVE H, FACON T, IFRAH N, PAYEN C, BATAILLE R. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective randomised trial. N Eng J Med 1996;335:91-97.
2. 2. GAHRTON G, TURA S, LJUNGMAN P, BLADE J, BRANDT L, CAVO M, FACON T, GRATWOHL A, HAGENBEEK A, JACOBS P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-1322.
3. 3. BENSINGER WI, BUCHNER CD, ANASETTI C, CLIFT R, STORB R, BARNETT T, CHAUNCEY T, SHULMAN H, APPLEBAUM FR. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2782-2793.
4. 4. RUSSELL NH, MIFLIN G, STAINER C, MCQUAKER JG, BENZ N, HAYNES AP, BESSELL EM. Allogeneic bone marrow transplantation for multiple myeloma. Blood 1997;89:2610-2611.
5. 5. GROSSBARD ML, FIDIAS P, KINSELLA J, O'TOOLE J, LAMBERT JM, BLATTLER WA, ESSELTINE D, BRAMAN G, NADLER LM, ANDERSON KC. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol 1998;102:509-515.
6. 6. VOOIJS WC, SCHUURMAN HJ, BAST EJ, DE GAST GC. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995;85:2282-2284.
7. 7. STEVENSON FK, BELL AJ, CUSACK R, HAMBLIN TJ, SLADE CJ, SPELLERBERG MB, STEVENSON GT. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77:1071-1079.
8. 8. ELLIS JH, BARBER KA, TUTT A, HALE C, LEWIS AP, GLENNIE MJ, STEVENSON GT, CROWE JS. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunology 1995;155:925-937.
9. 9. RAWSTRON AC, OWEN RG, DAVIES FE, JOHNSON RJ, JONES RA, RICHARDS SJ, EVANS PA, CHILD JA, SMITH GM, JACK AS, MORGAN GJ. Circulating plasma cells in multiple myeloma: characterisation and correlation with disease stage. Br J Haematol 1997;97:46-55.
10. 10. ORCHARD K, COOPER M, WIJDENES J, BORCHARDT P, QUADRI S, GREEN A, POTTER M, SAMSON D, APPERLEY J, BUSCOMBE J, HILSON A, MYERS M, PRETINCE G, AMLOT P, BEGENT R, MEHTA A. Radiolabelled antibody therapy for patients with multiple myeloma: results of pre-clinical evaluation of candidate antibodies and initial clinical studies. Proceedings of the VII International Multiple Myeloma Workshop 1999;Abstr.:46.
11. 11. GOTO T, KENNEL SJ, ABE M, TAKISHITA M, KOSAKA M, SOLOMON A, SAITO S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994;84:1922-1930.
12. 12. OZAKI S, KOSAKA M, WAKATSUKI S, ABE M, KOISHIHARA Y, MATSUMOTO T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997;90:3179-3186.
13. 13. TREON SP, MOLLICK JA, URASHIMA M, TEOH G, CHAUHAN D, OGATA A, RAJE N, HILGERS JHM, NADLER L, BELCH AR, PILARSKI LM, ANDERSON KC. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999;93:1287-1298.
14. 14. KAWANO M, HIRANO T, MATSUDA T, TAGA T, HORII Y, IWAO K, ASAOKU H, TANG B, TANABE O, TANAKA H, KURAMOTO A, KISHIMOTO T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-85.
15. 15. KLEIN B, ZHANG XG, JOURDAN M, CONTENT G, HOUSSIAU F, AARDEN L, PIECHACZYK M, BATAILLE R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin 6. Blood 1989;73:517-526.
16. 16. KISHIMOTO T, TAGA T, AKIRA S. Cytokine signal transduction. Cell 1994;76:253-262.
17. 17. KISHIMOTO T, AKIRA S, NARAZAKI M, TAGA T. Interleukin 6 family of cytokines and gp130. Blood 1995;86:1243-1254.
18. 18. OGATA A, CHAUHAN D, TEOH G, TREON SP, URASHIMA M, SCHLOSSMAN RL, ANDERSON KC. Interleukin 6 triggers cell growth via the ras dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-2221.
19. 19. OGATA A, CHAUHAN D, URASHIMA M, TEOH G, TREON SP, ANDERSON KC. Blockade of mitogen activated protein kinase cascade signalling in interleukin 6 independent multiple myeloma cells. Clin Cancer Res 1997;3:1017-1022.
20. 20. JERNBERG-WIKLUND H, PETTERSSON M, NILSSON K. Recombinant interferon-gamma inhibits the growth of IL-6 dependent human multiple myeloma cell lines in vitro. Eur J Haematol 1991;46:231-239.
21. 21. PORTIER M, ZHANG XG, CARON E, LU ZY, BATAILLE R, KLEIN B. Gamma-interferon in multiple myeloma: inhibition of interleukin-6 dependent myeloma cells growth and downregulation of IL-6 receptor expression in vitro. Blood 1993;81:3076-3082.
22. 22. OGATA A, NISHIMOTO N, SHIMA Y, YOSHIZAKI K, KISHIMOTO T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040-3046.
23. 23. SCHWABE M, BRINI AT, BOSCO MC, RUBBOLI F, EGAWA M, ZHAO J, PRINCLER GL, KUNG HF. Disruption by interferon α of autocrine IL6 growth loop in IL6 dependent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor alpha and beta chains. J Clin Invest 1994;94:2317-2325.
24. 24. KLEIN B, WIDJENES J, ZHANG XG, JOURDAN M, BOIRON JM, BROCHIER J, LIAUTARD J, MERLIN M, CLEMENT C, MOREL-FOURNIER B, LU ZY, MANNONI P, SANY J, BATAILLE R. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukaemia. Blood 1991;78: 1198-1204.
25. 25. VAN ZAANEN HC, LOKHORST HM, AARDEN LA, RENSINK HJ, WARNAAR SO, VANOERS MH. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. Leukaemia and Lymphoma 1998;31:551-558.
26. 26. KREITMAN RJ, SIEGALL CB, FITZGERALD DJ, EPSTEIN J, BARLOGIE B, PASTAN I. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 1992;79:1775-1780.
27. 27. CHADWICK DE, JEAN LF, JAMAL N, MESSNER HA, MURPHY JR, MINDEN MD. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diptheria toxin-interleukin 6 fusion protein. Br J Haematol 1993;85:25-36.
28. 28. SAVINO R, CIAPPONI L, LAHM A, DEMARTIS A, CABIBBO A, TONIATTI C, DELMASTRO P, ALTAMURA S, CILIBERTO G. Rational design of a receptor super-antagonist of human interleukin-6. Eur Molecular Biol Org J 1994;13:5863-5870.
29. 29. SPORENO E, SAVINO R, CIAPPONI L, PAONESSA G, CABIBBO A, LAHM A, PULKKI K, SUN RX, TONIATTI C, KLEIN B. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 1996;87:4510-4519.
30. 30. SUZUKI H, YASUKAWA K, SAITO T, GOITSUKA R, HASEGAWA A, OHSUGI Y, TAGA T, KISHIMOTO T. Anti-human interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992;22:1989-1993.
31. 31. TSUNENARI T, AKAMATSU K, KAIHO S, SATO K, TSUCHIYA M, KOISHIHARA Y, KISHIMOTO T, OHSUGI Y. Therapeutic potential of humanised anti-interleukin 6 receptor antibody: anti-tumor activity in xenograft model of multiple myeloma. Anticancer Res 1996;16:2537-2544.
32. 32. TSUNERNARI T, KOISHIHARA Y, NAKAMURA A, MORIYA M, OHKAWA H, GOTO H, SHIMAZAKI C, NAKAGAWA M, OHSUGI Y, KISHIMOTO T, AKAMATSU K. New xenograft model of multiple myeloma and efficacy of a humanised antibody against human interleukin 6 receptor. Blood 1997;90:2437-2444.
33. 33. RAWSTRON AC, ASHCROFT J, NEWTON L, DAVIES FE, CHILD JA, JACK AS, MORGAN GJ. IL6R is downregulated during normal plasma cell differentiation but remains on neoplastic plasma cells. Blood 1998;92:suppl. 1, abstr. 2618.
34. 34. FRANK DA. STAT signalling in the pathogenesis and treatment of cancer. Mol Med 1999;5:432-456.
35. 35. MEYDAN N, GRUNBERGER T, DADI H, SHAHAR M, ARPAIA E, LAPIDOT Z, LEEDER JS, FREEDMAN M, COHEN A, GAZIT A, LEVITZKI A, ROIFMAN CM. Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature 1996;379:645-648.
36. 36. DRUKER BJ, TAMURA S, BUCHDUNGER E, OHNO S, SEGAL GM, FANNING S, ZIMMERMANN J, LYDON NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996;2:561-566.
37. 37. MARRA F, CHOUDHURY GG, ABBOUD HE. Interferon γ mediated activation of STAT1α regulates growth factor induced mitogenesis. J Clin Invest 1996;98:1218-1239.
38. 38. NIEBOROWSKA-SKORSKA M, WASIK MA, SLUPIANEK A, SALOMONI P, KITAMURA T, CALABRETTA B, SKORSKI T. Signal transducer and activator of transcription (STAT)-5 activation by Bcr/Abl is dependent on intact Src homology (SH)3 and SH2 domains of Bcr/Abl, and is required for leukemogenesis. J Exp Med 1999;189:1229-1242.
39. 39. KAPLAN DH, SHANKARAN V, DIGHE AS, STOCKERT E, AGUET M, OLD LJ, SCHREIBER RD. Demonstration of an interferon γ dependent tumour surveillance system in immunocompetent mice. Proc Nat Acad Sci 1998;95:7556-7561.
40. 40. KAPLAN MH, SCHINDLER U, SMILEY ST, GRUSBY MJ. STAT6 is required for mediating responses to IL4 and for the development of th2 cells. Immunity 1996;4:313-319.
41. 41. SHIMODA K, VAN DEURSEN J, SANGSTER MY, SARAWAR SR, CARSON RT, TRIPP RA, CHU C, QUELLE FW, NOSAKA T, VIGNALI DA, DOHERTY PC, GROSVELD G, PAUL WE, IHLE JN. Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature 1996;380: 630-633.
42. 42. TAKEDA K, NOGUCHI K, SHI W, TANAKA T, MATSUMOTO M, YOSHIDA N, KISHIMOTO T, AKIRA S. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Nat Acad Sci 1997;94:3801-3804.
43. 43. CHAUHAN D, KHARBANDA S, OGATA A, URASHIMA M, TEOH G, ROBERTSON M, KUFE DW, ANDERSON KC. Interleukin 6 inhibits Fas induced apoptosis and stress activated protein kinase activation in multiple myeloma cells. Blood 1997; 89:227-234.
44. 44. CHAUHAN D, PADEY P, OGATA A, TEOH G, TREON S, URASHIMA M, KHARBANDA S, ANDERSON KC. Dexamethasone induced apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997;15: 837-843.
45. 45. CHAUHAN D, PANDEY P, AVRAHAM S, HIDESHIMA T, TREON SP, RAJE N, DAVIES FE, TAI YT, SHIMA Y, KHARBANDA S, ANDERSON KC. Interleukin-6 induced SHP2 activation mediates resistance to dexamethasone induced RAFTK activation and apoptosis in multiple myeloma cells. Blood 1999;94:Suppl 1, abstr. 3103.
46. 46. CHAUHAN D, PANDREY P, OGATA A, TEOH G, KRETT N, HALGREN R, ROSEN S, KUFE D, KHARBANDA S, ANDERSON KC. Cytochrome c dependent and independent induction of apoptosis in multiple myeloma cells. J Biochem Chem 1997;272:29995-29997.
47. 47. OKADA, T, HAWLEY RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int J Cancer 1995;63:823.
48. 48. UCHIYAMA H, BARUT BA, CHAUHAN D, CANNISTRA SA, ANDERSON KC. Characterisation of adhesion molecules in human myeloma cell lines. Blood 1992;80:2306-2314.
49. 49. TEOH G, ANDERSON KC. Interaction of tumour and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin N Am 1997;11:27-42.
50. 50. RAWSTRON AC, BARRANS SI, BLYTHE D, DAVIES FE, ENGLISH A, PRATT G, CHILD JA, JACK AS, MORGAN GJ. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999:104:138-143.
51. 51. URASHIMA M, CHAUHAN D, UCHIYAMA H, FREEMAN GJ, ANDERSON KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995;85:1903-1912.
52. 52. TEOH G, URASHIMA M, GREENFIELD EA, NGUYEN KA, LEE JF, CHAUHAN D, OGATA A, TREON SP, ANDERSON KC. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest 1998;101:1379-1388.
53. 53. URASHIMA M, OGATA A, CHAUHAN D, HATZIYANNI M, VIDRIALES MB, DEDERA DA, SCHLOSSMAN RL, ANDERSON KC. Transforming growth factor beta: differential effects on multiple myeloma versus normal B cells. Blood 1996; 87:1929-1938.
54. 54. URASHIMA M, CHEN BP, CHEN S, PINKUS GS, BRONSON RT, DEDERA DA, HOSHI Y, TEOH G, OGATA A, TREON SP, CHAUHAN D, ANDERSON KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-765.
55. 55. SCHULTZE JL, ANDERSON KC, GILLFECE MH, MICHALAK S, HICKEY A, WEBB I, GRIBBEN JG, NADLER LM. Autologous adoptive T cell transfer for a patient with plasma cell leukemia: results of a pilot phase 1 trial. Blood 1998;92: suppl 1, abstr. 446.
56. 56. VACCA A, RIBATTI D, PRESTA M, MINISCHETTI M, LURLARO M, RIA R, ALBINI A, BUSSOLINO F, DAMMACCO F. Bone marrow neovascularisation, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073.
57. 57. MUNSHI N, WILSON CS, PENN J, EPSTEIN J, SINGHAL S, HOUGH A, SANDERSON R, DESIKAN R, SIEGAL D, MEHTA J, BARLOGIE B. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood 1998;92:suppl 1, abstr. 400.
58. 58. RAJKUMAR SV, FONSECA R, WITZIG TE, GERTZ MA, GRIEPP PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999;13:469-472.
59. 59. SINGHAL S, MEHTA J, DESIKAN R, AYERS D, ROBERSON P, EDDLEMON P, MUNSHI N, ANAISSIE E, WILSON C, DHODAPKAR M, ZEDDIS J, BARLOGIE B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;18: 1565-1571.
60. 60. WEBER DM, GAVINO M, DELASALLE K, RANKIN K, GIRALT S, ALEXANIAN R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999;94:suppl 1, abstr. 2686.
61. 61. GEITZ H, HANDT S, ZWINGENBERGER K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221.
62. 62. HASLETT PAJ, CORRAL LG, ALBERT M, KAPLAN G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytokine responses in the CD8+ subset. J Exp Med 1998;187:1885-1892.
63. 63. CORRAL LG, HASLETT PAJ, MULLER GW, CHEN R, WONG LM, OCAMPO CJ, PATTERSON RT, STIRLING DI, KAPLAN G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNFα. J Immunol 1999;163:380-386.
64. 64. SJAK-SHIE N, SULUR G, SAID J, VESCIO R, BERENSON J. Angiogenesis and vascular endothelial growth factor expression correlate with the degree of bone marrow involvement in multiple myeloma patients. Proceedings of the VII International Multiple Myeloma Workshop 1999; abstr. 154.
65. 65. BELLAMY WT, RITCHER L, FRUTIGER Y, GROGAN TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
66. 66. DANKBAR B, PADRO T, MESTERS RM, LEO R, OSTERMANN H, SERVE H, BERDEL WE, KIENAST J. VEGF is expressed by myeloma cells and stimulates IL-6 secretion by microvascular endothelial and bone marrow stromal cells. Blood 1998;92:Suppl1 Abstr. 2807.
67. 67. SONNEVELD, DURIE BG, LOKHORST HM, FRUTIGER Y, SCHOESTER M, VELA EE. Analysis of multidrug resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol 1993;83:63-67.
68. 68. SALMOM SE, DALTON WS, GROGAN TM, PLEZIA P, LEHNERT M, ROE DJ, MILLER TP. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitiser. Blood 1991;78:44-50.
69. 69. SONNEVELD P, DURIE BG, LOKHORST HM, MARIE JP, SOLBU G, SUCIU S, ZITTOUN R, LOWENBERG B, NOOTER K. Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-259.
70. 70. COLE SP, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWART AJ, KURZ EU, DUNCAN AM, DEELEY RG. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 1992;258: 1650-1654.
71. 71. IZQUIERDO MA, SCHEFFER GL, FLENS MJ, SCHROEIJERS AB, VAN DER VALK P, SCHEPER RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996;32A: 979-984.
72. 72. RISZA LM, CAMPBELL K, DALTON WS, SALMON S, WILCOX G, GROGAN TM. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leukaemia and Lymphoma 1999;34:315-324.
73. 73. FUTSCHER BW, FOLEY NE, GLEASON-GUZMAN MC, MELTZER PS, SULLIVAN DM, DALTON WS. Verapamil suppresses the emergence of P-glycoprotein-mediated multidrug resistance. Int J Cancer 1996;66:520-525.
74. 74. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM, TURKSON J, LEVITZKI A, SAVINO R, CILBERTO G, MOSCINSKI L, FERNANDEZ-LUNA JL, NUNEZ G, DALTON WS, JOVE R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115.